News archive

Learn how fatigue, emotional wellbeing, and shared decision-making shape patient-centered care for those living with immune thrombocytopenia (ITP).

For many people living with hidradenitis suppurativa (HS), the hardest part isn’t finding treatment—it’s getting a timely diagnosis. A new collaboration between Novartis and the American Academy of Dermatology combines real-world data and AI tools to provide patients with hope.

Younos Abdulsattar, PharmD, a Novartis medical team leader, breaks down the 2026 cholesterol guidelines, and what patients need to know about LDL-C, Lp(a), and heart health.

The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.

1 in 5 Americans lives with an autoimmune disease, yet many have no or very limited treatment options. Christy Siegel, SVP and TA Head, Immunology, Novartis US, shares how we aim to change that.

Colin works on a cryo-electron microscope the size of a room using a process that earned a team of scientists a Nobel Prize. Learn how his work is advancing the ways we treat disease.

For World Sjögren's Day, dancer and TV personality Carrie Ann Inaba shares her story of diagnosis, living with the disease, and self-advocacy 

The hidradenitis suppurativa (HS) Community Mapping Project surveyed patients to create a roadmap for change. Here's what they shared.

For Carter Jaynes, helping to produce doses of RLT is deeply personal. See how a move to our new RLT facility in Carlsbad can help him reach even more patients.

In a nationwide survey, more than 2,000 patients, caregivers, and clinicians told us what cancer care gets right, and where we can collaborate to improve. 

A year ago, we committed to investing $23 billion in America’s health over the next five years. Here’s a look at the impact we’ve made so far—plus a new initiative we’re launching in five cities to drive awareness and earlier detection of breast and prostate cancer.